À¯·´ÀǾàǰû(EMA¡¤ European Medicines Agency)Àº Ä¡·á°¡ ¾î·Á¿î Ç÷¾×¾Ï Ä¡·áÁ¦ÀÎ ³ë¹ÙƼ½º»çÀÇ Rydapt(midostaurin) ½ÂÀÎÀ» ÃßõÇÑ´Ù°í ¹àÇû´Ù.
21ÀÏ(ÇöÁö½Ã°¢) ·ÎÀÌÅÍ Åë½ÅÀº À¯·´ÀǾàǰûÀÇ ¹ßÇ¥¸¦ Àοë, À̰°ÀÌ º¸µµÇß´Ù.
À¯·´ÀǾàǰûÀÇ À¯·´ ¾à¹°»ç¿ë ÀÚ¹®À§¿øÈ¸(Committee for Medicinal Products for Human Use ; CHMP)´Â ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(acute myeloid leukaemia, AML)À¸·Î »õ·Ó°Ô Áø´ÜµÈ ȯÀÚ¿Í 3°¡Áö ´Ù¸¥ Áõ»ó Ä¡·á ¸ñÀûÀ¸·Î Rydapt ½ÂÀÎÀ» ÃßõÇÑ´Ù°í ¹àÇû´Ù.
¶ÇÇÑ ½ÅüÀÇ ºñ¸¸ ¼¼Æ÷°¡ ºü¸£°Ô Áõ½ÄµÇ´Â Àü½Åºñ¸¸¼¼Æ÷Áõ (advanced systemic mastocytosis) ¼ºÀΠȯÀÚ Ä¡·áÁ¦·Îµµ ½ÂÀÎÀ» ÃßõÇß´Ù.
¹Ì±¹¼ 2ÁÖºÐÀÇ Rydapt µµ¸Å ¾à°ªÀº 7,500´Þ·¯ÀÌ¸ç ¹Ì±¹¿¡¼´Â 4¿ù FDA ½ÂÀÎµÈ ¹Ù ÀÖ´Ù.